Skip to content

Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods

Robot-assisted Gait Training in Patients Affected by Multiple Sclerosis: Rehabilitative Efficacy Evaluation and Comparison With Traditional Methods

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02291107
Enrollment
17
Registered
2014-11-14
Start date
2014-06-30
Completion date
2016-06-30
Last updated
2015-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Gait orthosis, Lokomat, Robotic Rehabilitation

Brief summary

In Multiple Sclerosis (MS) gait disorders represent one of the most disabling aspect that strongly influence patient quality of life. The improvement of walking ability is a primary goal for rehabilitation treatment. Current promising rehabilitative approaches for neurological disorders are based on the concept of the task-specific repetitive training. Hence, the interest in automated robotic devices that allow this typology of treatment for gait training. However, studies on the effectiveness of such methodologies are still poorly numerous in terms of functional improvement in MS patients. The aim of this controlled cross-over study is to evaluate the effectiveness of a Lokomat gait training in patients affected by Multiple Sclerosis in comparison to a ground conventional gait training.

Detailed description

In Multiple Sclerosis (MS), the highly variable distribution of demyelinization areas and axonal loss in the Central Nervous System can lead to very complex and unpredictable neurological deficits and clinical patterns. Gait disorders as reduced speed and stride length, gait asymmetry, increased muscular energy expenditure, balance deficit and increased risk of falling, represent one of the most disabling aspect. These motor problems strongly influence the level of independence that a person affected by MS is able to achieve, resulting in severe negative impact on quality of life. Therefore, the improvement of walking ability is a primary goal for rehabilitation treatment. Many studies demonstrated that a conventional rehabilitation treatment based on physiotherapy could be effective in increasing muscle strength and motor function, improving gait and mobility abilities, reducing fatigue and risk of falls, leading finally to an overall increase of patient autonomy. According to the most recent neurophysiological concepts based on neural plasticity, in recent years the rehabilitative approaches that seem to be more effective in improving functional performance are based on the concept of the task-specific repetitive training. As in the case of the constraint induced movement therapy (CIMT) for upper limb rehabilitation and the body weight support treadmill training (BWSTT) for the lower, the factors that appear to positively affect patient outcome are the intensity, precocity, repeatability, specificity in a training that incorporates high numbers of repetitions of task-oriented practice. Hence, the interest in automated robotic devices for gait training for MS patients has grown. With their consistent, symmetrical lower-limb trajectories, robotic devices provide many of the proprioceptive inputs that may increase cortical activation and stimulation of Central Pattern Generator (CGPs) in order to improve motor function. The use of robot-assisted-gait-training (RAGT) allows: repetition of specific and stereotyped movements in order to acquire a correct and reproducible gait pattern in conditions of balance and symmetry, early start of treatment using the activity with body weight support, safeguard of the patient with reduction of fear of falling, in order to increase the quantity and quality of the performed exercise while minimizing the intervention of a therapist. However, studies on the effectiveness of such methodologies are still poorly numerous in terms of functional improvement in patients with MS. The aim of this controlled cross-over study is to evaluate the effectiveness of a robot-driven gait orthosis (Lokomat - Hocoma, Inc., Zurich, Switzerland) gait training in patients affected by Multiple Sclerosis in comparison to a ground conventional gait training. The improvement in gait pattern, motor ability and autonomy in the functional activities of daily living will be assessed by using validated clinical and functional scales and quantitative instrumental analysis of gait kinematic parameters

Interventions

Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.

OTHERConventional Physiotherapy

Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.

Sponsors

Habilita, Ospedale di Sarnico
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* diagnosis of multiple sclerosis according to the McDonald's Criteria in stable phase of disease for at least 3 months. * ability to walk 25 foot without assistance * EDSS score between 3.5 and 7

Exclusion criteria

* exacerbations of the disease in the last 3 months * deficits of somatic sensation involving the legs * other neurological, orthopedic or cardiovascular co-morbility * severe posture abnormalities * severe-moderate cognitive impairment (Mini Mental State ≤ 21) * body weight greater than 135 kg; * height more than 200 cm; * limb-length discrepancy greater than 2 cm; * presence of skin lesions on the trunk, pelvis and lower limbs that could interfere with the placement of the electrodes and straps anchoring the Lokomat.

Design outcomes

Primary

MeasureTime frameDescription
Timed 25 Foot Walk (25FW)5 weeksAssessment of gait performance in terms of speed. First component of the Multiple Sclerosis Functional Composite (MSCF) scale - leg function / ambulation, for the study and measurement of functional outcomes in clinical trials in patients with multiple sclerosis according to the Task Force on Clinical Outcomes Assessment of the National Multiple Sclerosis Society - 1994.

Secondary

MeasureTime frameDescription
6 minute walking test (6MWT)5 weeksAssessment of gait performance in terms of resistance
Tinetti Test (TT)5 weeksAssessment of balance and gait ability and the falls risk
Functional Ambulation Categories (FAC)5 weeksAssessment of ambulation ability
Modified Ashworth scale for lower limbs5 weeksAssessment of lower limbs spasticity
Modified Motricity Index for lower limbs5 weeksAssessment of lower limbs motor function
Knee extensor strength (KES)5 weeksAssessment of knee extensor strength by dynamometer measurement
Timed 10 meter walking test (TWT)5 weeksAssessment of gait performance in terms of speed
Step Length Ratio (SLR)5 weekskinematic parameter corresponding to gait symmetry, calculated as the ratio between the step length of both legs (shorter step length / longer step length)
Expanded Disability Status Scale (EDSS)5 weeksTraditionally used disability scale for multiple sclerosis
Functional Independence Measure (FIM)5 weeksAssessment of daily activities functional autonomy
Quality of Life Index (QL Index - SF36)5 weeksMeasures of health-related quality of life
Numeric Rating Scale (NRS)5 weeksAssessment of pain
Double Time Support (DST)5 weekskinematic parameter corresponding to the duration of the double support phase of gait cycle, calculated as \[ms /%\]

Countries

Italy

Contacts

Primary ContactCristiano Sconza, MD
cristiano.sconza@gmail.com0354815515

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026